Stockreport

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech Inc. - Common Shares  (ONCY) 
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com
PDF Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR  Combination achieved encouraging median DOR of almost 17 months Data establishes clea [Read more]